Research and development

Our unified R&D organisation brings together expertise in three core technology platforms, Injectables, Respiratory, Nasal, Semi-Solids and Liquids, and Solid Orals, to drive continued growth

Strategic pillars strengthening our organisation

  • Injectables
  • Respiratory, Nasal, Semi-Solids and Liquids 
  • Solid Orals
  • Unified criteria for selecting internal products and BD/M&A opportunities
  • Disciplined investments that deliver strong returns and long-term growth
Expertise in three core technology platforms supported by global R&D operations
Injectables Formulation development, analytical development, medical science injectables, new product transfer
Respiratory, Nasal, Semi-Solids and Liquids Formulation development, analytical development, clinical, product transfer
Solid Orals Formulation development, analytical development, clinical, product transfer
R&D operations and Regulatory Affairs Driving consistency, efficiency, impact and harmonised tools
Decorative image.
Leveraging global synergies, expertise and alignment

Q&A with Hafrun Fridriksdottir, EVP, Rx and R&D

Product selection sits at the heart of what we do. It's not a one-time exercise but a continuous, dynamic process where we constantly reprioritise our pipeline based on value creation and the competitive landscape.

Our R&D leaders

Hafrun Fridriksdottir - EVP, Rx and R&D

Chris Edlin - VP, Respiratory, Nasal, Semi-Solids Liquids

Zdravka Knezevic - VP, Injectables

Jaber Qasem - VP, Solid Orals

Ragheb AbuRmaileh - VP, R&D Operations

Dawn Culp - VP, Regulatory Affairs EU & US

Discover what it's like to work at Hikma through our employee testimonials

Innovating with purpose: R&D at Hikma

Careers at Hikma